OrthoSpineNews

SEPTEMBER 24, 2024

NEW YORK, September 24, 2024 –(BUSINESS WIRE)– Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase 3 clinical trial of SB-01 For Injection (SB-01).

Degenerative Disc Disease 94

Degenerative Disc Disease Spine Clinic 94

OrthoSpineNews

JULY 16, 2024

Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 16, 2024 /PRNewswire/ — DiscGenics, Inc.,

Degenerative Disc Disease 52

Degenerative Disc Disease Clinic Musculoskeletal Spine 52

OrthoSpineNews

JULY 11, 2024

July 11, 2024 /PRNewswire/ — Providence Medical Technology announces FDA Clearance of its CORUS™ Posterior Cervical Stabilization System (PCSS) for the treatment of up to 3-level cervical Degenerative Disc Disease (DDD).

Degenerative Disc Disease 52

Degenerative Disc Disease Clinic Spine Treatment 52

OrthoSpineNews

JUNE 23, 2025

Food and Drug Administration (FDA) premarket approval (PMA) of PearlMatrix P-15 Peptide Enhanced Bone Graft as a Class III drug-device combination product for use in single-level transforaminal lumbar interbody fusion (TLIF) surgery in adult patients with degenerative disc disease (DDD). 3 The ASPIRE trial included 33 U.S.

52

52

OrthoSpineNews

MAY 14, 2025

We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025, said Lance Alstodt, the Companys Chief Executive Officer. First quarter 2025 deferred revenues were $150,000, compared to $nil in the first quarter of 2024. million in the first quarter of 2024.

Degenerative Disc Disease 52

Degenerative Disc Disease Lower Back Pain Neck Pain Treatment 52

OrthoSpineNews

FEBRUARY 10, 2025

Explore trends, segmentation, and growth drivers- View Free Sample PDF Spinal Implants Market Scope Report Coverage Details Base year 2024 Historic period 2019 – 2023 Forecast period 2025-2029 Growth momentum & CAGR Accelerate at a CAGR of 5.3% Key insights into market evolution with AI-powered analysis. JAYON IMPLANTS Pvt.

Degenerative Disc Disease 40

Degenerative Disc Disease Scoliosis Clients Spine 40